Role of Bcl-2 -938 C>A polymorphism in susceptibility and prognosis of cancer: a meta-analysis

• Published in: Scientific reports 2014-11, Vol.4 (1), p.7241-7241, Article 7241
• Main Authors: Zhang, Xiao, Weng, Wenhao, Xu, Wen, Wang, Yulan, Yu, Wenjun, Tang, Xun, Ma, Lifang, Pan, Qiuhui, Wang, Jiayi, Sun, Fenyong
• Format: Article
• Language: English
• Subjects: 38; 45; 631/208/737/211/2120; 631/67/68; Aged; Alleles; Asian Continental Ancestry Group - genetics; B-cell lymphoma; Bcl protein; Bcl-2 protein; Cancer; Case-Control Studies; European Continental Ancestry Group - genetics; Female; Genetic Predisposition to Disease - genetics; Health risk assessment; Humanities and Social Sciences; Humans; Lymphocytes B; Male; Medical prognosis; Meta-analysis; Middle Aged; multidisciplinary; Neoplasms - genetics; Neoplasms - pathology; Polymorphism, Genetic - genetics; Prognosis; Proto-Oncogene Proteins c-bcl-2 - genetics; Risk; Risk Factors; Science
• ISSN: 2045-2322; 2045-2322
• DOI: 10.1038/srep07241

The association between B-cell lymphoma 2 ( Bcl-2 ) polymorphism and cancer is under debate and remains elusive. This meta-analysis was performed to evaluate the relationships of Bcl-2 -938 C>A polymorphism (rs2279115) with susceptibility and prognosis of cancer. Odds ratios (ORs) were used to measure the association between Bcl-2 polymorphisms and cancer risk. Hazard ratios (HRs) were used to measure the association between Bcl-2 polymorphisms and cancer prognosis. On the basis of 26 studies about Bcl-2 -938C>A polymorphism and cancer, we found Bcl-2 -938 C>A polymorphism was significantly associated with increased cancer risk in dominant model (OR = 1.12, 95%CI: 1.00–1.25, P = 0.04), recessive model (OR = 1.38, 95%CI: 1.11–1.71, P = 0.004), allelic model (OR = 1.15, 95%CI: 1.04–1.28, P = 0.007) and homozygote comparison(OR = 1.44, 95%CI: 1.11–1.87, P = 0.006). Furthermore, Bcl-2 -938 C>A polymorphism was significantly associated with increased cancer risk in Asians but not in Caucasians. Moreover, Bcl-2 -938 C>A polymorphism was not significantly associated with the prognosis of cancer (AA vs CA: OR = 0.99, 95%CI: 0.77–1.27, P = 0.93; AA vs CC: OR = 0.92, 95%CI: 0.65–1.30, P = 0.63; AC vs CC: OR = 0.94, 95%CI: 0.80–1.11, P = 0.48; CC vs AA+CA: OR = 1.21, 95%CI: 0.69–2.13, P = 0.50; AA vs CC+CA: OR = 0.99, 95%CI: 0.48–2.04, P = 0.97). Studies with larger samples and gene-environment interactions are needed to validate our findings.